



CBD MED RESEARCH CORP

#810 – 675 W. Hastings Street, Vancouver, B.C., Canada V6B 1N2
Tel: 604-802-7551 • www.cbdmedresearch.com

December 19, 2016

CBD MED RESEARCH CORP. ("CBM" or the "Company")

TSX.V NEX Symbol: CBM.H

CBD MED Research Corp. Announces Closing of Unit Private Placement

December 19, 2016: CBD MED Research Corp.: The Company announces that it has received TSX Venture Exchange ("Exchange") acceptance of the closing of the second tranche of a unit private placement which was also approved by shareholders at the company recent Annual General Meeting held Nov 29th 2016 in Vancouver BC. The current second tranche is a portion of the private placement originally announced on February 24, 2015 and confirmed in a news release dated April 14, 2016. Each unit is composed of one share ("Share") and one share purchase warrant ("Warrant") to acquire one further Share ("Warrant Share") exercisable at a price of \$.08 per Warrant Share with a one year term ("Unit"). The Company will close the second tranche upon issuance of the Exchange bulletin accepting the private placement and issue 5,904,049 Units at a price of \$.06 per Unit by the issue of 5,904,049 Shares and 5,904,049 Warrants. The Shares and Warrant Shares will be subject to a four month hold and one day hold period from the date of issue of the Warrants. A news release will be issued announcing the date of Closing.

By the end of 2016 the Company will also issue a news release regarding the status of the of the transaction with Medipacs Inc.

On behalf of the Board of Directors,

CBD Med Research Corp.

"Gary F. Zak"

President, CEO

Email: gzak1@shaw.ca

Tel: 604-802-7551

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release includes certain statements that may be deemed "forward-looking statements". For more information on the Company and the risks and challenges of its business, investors should review the Company's annual filings that are available at www.sedar.com